Actively Recruiting
Gustave Roussy Cancer Profiling
Led by Gustave Roussy, Cancer Campus, Grand Paris · Updated on 2026-02-06
20000
Participants Needed
4
Research Sites
626 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.
CONDITIONS
Official Title
Gustave Roussy Cancer Profiling
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 2 18 years
- Diagnosis of a solid malignant tumor or hematological malignancy
- Patient has social security complying with French biomedical research law
- Voluntary signed and dated informed consent before any study procedure
You will not qualify if you...
- Any condition that makes participation undesirable or threatens protocol compliance as judged by the Investigator
- Under guardianship, deprived of liberty by judicial or administrative decision, or unable to give consent
- Pregnant or breastfeeding women
- Minors under 18 years old
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, France, 94805
Actively Recruiting
2
Hôpital Marie-Lannelongue
Le Plessis-Robinson, France, 92350
Actively Recruiting
3
Hôpital Saint-Joseph
Paris, France, 75014
Not Yet Recruiting
4
Hôpital Foch
Suresnes, France, 92150
Not Yet Recruiting
Research Team
A
Antoine Italiano, MD PhD
CONTACT
C
Clementine MAHAUT
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here